🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🔥debate between Juan Pablo (JP) Arab, MD  and Dr. Brian Lee regarding “should hepatologists provide comprehensive care management for individuals with AUD” !! What’s your stand?! #alcoholfree Digestive Disease Week AASLD

Challenge the guideline: 🌟Baclofen may NOT be safe for ALD compensated cirrhosis, per our multicenter cohort with lab data and longitudinal follow up 🌟Previous RCT that supported baclofen only had <40 pts using baclofen and was not powered for safety 🌟Call upon Motivational

While cigarette taxes are at all-time high, alcohol taxes are at all-time lows!! An important tax that our government should tackle… #MedTwitter #Medicine #alcoholfree #Health #policy AASLD American Gastroenterological Association (AGA) ACG Liver Health Foundations

Our machine learning prediction model for ACLF mortality got Poster of Distinction. 👍outperforms CLIF-C ACLF and MELD 3.0 👍An explainable ML model —> not blackbox ML model anymore 👍A easy-to-use website for clinicians and researchers ❌not all organ failures are equally bad

Huge shout out to our incredible mentor, Ju Dong, and my extremely talented co-fellow, Jeff!! They developed a biomarker-derived index to risk stratify patients with LIRADS 3&4 lesions. #DDW2025 #HCC #biomarker

The FDA just completed its first AI-assisted scientific review—marking a historic shift in how new therapies are evaluated. Tasks that took days now take minutes. An AI revolution is underway inside the agency. If this is the start, what’s next? ⚖️🤖💊 fda.gov/news-events/pr…

Tirzepatide was superior to semaglutide with respect to weight loss and waist circumference at week 72. nejm.org/doi/full/10.10…

Excited to share our latest review on Alcohol-Associated Hepatitis (AH) trials! 📌 Emerging therapies targeting gut-liver axis, inflammation, oxidative stress, and liver regeneration show promise… 📌 Clinical trials in AH face ongoing challenges… sciencedirect.com/science/articl…

📢 It’s OVER. The “lean MASLD paradox”? Just bad measurement. ❎MASLD with overweight BMI weren’t healthier! We were using the wrong metric. ↗️Waist circumference-related indices show a dose-dependent mortality risk across 3 prospective cohorts. Let’s reframe how we assess

Hepatitis A outbreak in Los Angeles County! Please read and protect yourself. publichealth.lacounty.gov/phcommon/publi… tinyurl.com/yhuaurx2

Differences in Hepatocellular Carcinoma Incidence Trends Across US Census Divisions, 2001 to 2021. pubmed.ncbi.nlm.nih.gov/40361358/

This study found underutilization of post-discharge pharmacological and psychiatric interventions for alcohol relapse prevention therapy. ja.ma/3H3RtKH @hepating Yee Hui Yeo

👎We’re failing patients with alcohol-associated liver disease 🏥 ALD admissions: 11.5k → 37.5k (2014–2023) Among ALD admissions, within 1 year post-discharge: 💊 Medication rates barely reached 24% 🧠 Any psychiatric visit remained at 6.5% in 2023!!! 👥 Sex disparity:

Vinay Sundaram’s work on post-transplant survival in ACLF-3 at APEH

An important message on naltrexone in patients with liver disease: ✅Naltrexone can help reduce alcohol use without harming the liver. 🚫Alcohol DOES harm the liver. We do not need any more barriers to treat patients with AUD➕ALD! @nejm Elliot Tapper nejm.org/doi/full/10.10…

Alcohol Use and Cardiovascular Disease: A Scientific Statement From the American Heart Association: Circulation 🥸 Great work from AHA Science 😱 No level of alcohol is truly “safe”: Summary 👇👇👇

Muscle mass loss in people aged 65+ taking GLP-1 drugs acpjournals.org/doi/10.7326/AN… Annals of Int Med Emphasis on resistance training (RET) and close monitoring recommended

👏 Congratulations to Joseph C. Ahn, M.D. of Mayo Clinic, recipient of the 2025 Clinical, Translational, and Outcomes Research Award in #LiverDisease! His work harnesses #AI-generated data to improve prognostic models & clinical trial design in alcohol-associated hepatitis.